Akinleye A, Chen Y, Mukhi N et al (2013) Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol 6:59Akinleye, A., Chen, Y., Mukhi, N., Song, Y., and Liu, D. (2013) Ibrutinib and novel BTK inhibitors in clinical development, J Hematol Oncol 6, 59....
[3] De Rooij, M. F. et al. The clinically active BTK inhibitor PCI-32765targets B-cell receptor- and chemokinecontrolled adhesion and migration inchronic lymphocytic leukemia.Blood,2012, 119: 2590–2594. [4] Rule, S., & Chen, R. W....
Btk inhibitors have previously been tested and found to be efficacious in the NZB/W [4], [6], MRL/lpr[7], and B6.Sle1 [5] mouse models of SLE. However, these models do not recapitulate all the different subsets of lupus patients, and therefore there is a gap in knowledge as to ...
14. Kaptein A, de Bruin G, Hoek M E. Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies: American Society of Hematology, 2018. 15. Song Y, Xu W, Song Y, et al. Pooled Ana...
[1] Wen, T., Wang, J., Shi, Y. et al. Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances. Leukemia 35, 312–332 (2021). [2] Sun SL, Wu SH, Kang JB et al. Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors aga...
Btk inhibition has emerged as an attractive target for therapeutic intervention in human B-cell malig-nancies and autoimmune disorders. This review summarized the mechanism of Btk inhibitors and recent developments of Btk inhibitors already launched or in clinical trial. 【期刊名称】《药学研究》 【年...
1.Jian Hong,et al, Next-generation Bruton’s Tyrosine Kinase (BTK) Inhibitors Potentially ...
[5] 泽布替尼,能成为best in class吗?BTK抑制剂最新临床数据对比。医药魔方,2019年6月24日 [6]U.S. FOOD AND DRUG ADMINISTRATION, https://www.fda.gov/ [7] Feng Y, Duan W, Cu X, Liang C, Xin M, Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-201...
The following small-molecule Btk inhibitors in development were listed there: Stage of Company Compound Indications Development Pharmacyclics, Ibrutinib/ R/R CLL/SLL, MCL, Phase Ib/ Janssen PCL-32765 FL, DLBCL, MM, IIPhase indolent NHL, III(CLL/ MALT/MZL NHL) Pharmacyclics, PCL-32765 + R/R...
an overview of the mechanisms by which BTK contributes to immune-related diseases and summarizes current research on the development of BTK inhibitors for treating these conditions, aiming to offer novel insights into non-oncology applications for BTK inhibitors.Key...